{"id":"NCT01968980","sponsor":"Pfizer","briefTitle":"A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia","officialTitle":"A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-23","primaryCompletion":"2016-04-15","completion":"2016-04-15","firstPosted":"2013-10-24","resultsPosted":"2017-05-19","lastUpdate":"2017-06-26"},"enrollment":370,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Heterozygous Familial Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Bococizumab (PF-04950615;RN316)","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Bococizumab (PF-04950615;RN316)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multicenter, randomized study in subjects with heterozygous familial hypercholesterolemia receiving highly effective statins to assess the safety, efficacy and tolerability of Bococizumab (PF-04950615; RN316) to lower LDL-C.","primaryOutcome":{"measure":"Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-0.3,"sd":18.3},{"arm":"PF--04950615","deltaMin":-54.2,"sd":29.34}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":88,"countries":["United States","Bulgaria","Canada","Finland","Italy","Netherlands","Norway","Poland","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["37994400","37658997","35277540","29685591","28304227"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481021&StudyName=A%2052%20Week%20Study%20To%20Assess%20The%20Use%20Of%20RN316%20%28PF-04950615%29%20In%20Subjects%20With%20Heterozygous%20Familial%20Hypercholesterolemia"]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":185},"commonTop":["Injection site reaction","Nasopharyngitis","Headache","Upper respiratory tract infection","Influenza"]}}